6,945 results match your criteria Annals Of Hematology[Journal]


Correction to: Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.

Ann Hematol 2022 May 24. Epub 2022 May 24.

Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 ShuaiFuYuan Street, Dongcheng District, Beijing, 100730, China.

View Article and Full-Text PDF

Prevalence and characteristics of inflammatory rheumatic diseases in patients with thalassemia.

Ann Hematol 2022 May 23. Epub 2022 May 23.

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 50200, Chiang Mai, Thailand.

Reports of inflammatory rheumatic diseases (IRD) in thalassemia are limited. This study aimed to determine the prevalence and clinical characteristics of IRD in patients with thalassemia disease. Consecutive adult patients with thalassemia disease, confirmed by hemoglobin typing, attending the Hematology Clinic between June 2019 and May 2021 were invited to join this study. Read More

View Article and Full-Text PDF

Significance of alveolar nitric oxide concentration in the airway of patients with organizing pneumonia after allogeneic hematopoietic stem cell transplantation.

Ann Hematol 2022 May 23. Epub 2022 May 23.

Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan.

Organizing pneumonia (OP) is a complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and a manifestation of peripheral airway/alveolar inflammation. Recently, alveolar nitric oxide concentration (Calv) has been revealed as a noninvasive marker of peripheral airway inflammation; however, whether Calv levels are associated with OP and peripheral airway in patients after allo-HSCT remains unclear. Herein, we evaluated whether Calv levels could reflect the presence of OP and structural airway changes in patients after allo-HSCT. Read More

View Article and Full-Text PDF

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.

Ann Hematol 2022 May 21. Epub 2022 May 21.

Department of Hematology and Oncology, III. Medical Clinic, University Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors is limited. In this single-center study, antibody levels of the SARS-CoV-2 spike protein were measured ≥ 2 weeks after 2nd COVID-19 vaccination with a concentration ≥ 0. Read More

View Article and Full-Text PDF

Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.

Ann Hematol 2022 May 20. Epub 2022 May 20.

Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

The optimal follow-up care for relapse detection in acute myeloid leukemia (AML) patients in first remission after consolidation therapy with intensive chemotherapy is not established. In this retrospective study, we evaluate the diagnostic value of an intensive relapse surveillance strategy by regular bone marrow aspirations (BMA) in these patients. We identified 86 patients with newly diagnosed non-promyelocytic AML who had reached complete remission (CR) after intensive induction and consolidation chemotherapy between 2007 and 2019. Read More

View Article and Full-Text PDF

Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.

Ann Hematol 2022 May 19. Epub 2022 May 19.

Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy.

We report herein a multicentre retrospective analysis of 192 consecutive patients with symptomatic refractory/relapsed multiple myeloma (RRMM) treated with daratumumab in combination with bortezomib or lenalidomide as salvage therapy at 9 haematological centres in Puglia. Choice of both regimens was based on previous treatment and/or physicians' preference. Considering the under-representation of older patients (very old patient ≥ 80 years) in clinical trials and the prognostic and predictive importance and value of frailty status, here, we further characterised the patient cohort by age. Read More

View Article and Full-Text PDF

First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.

Ann Hematol 2022 May 18. Epub 2022 May 18.

Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, China.

Chemotherapy combined with radiotherapy could reduce the risk of recurrence in early-stage extranodal NK/T lymphoma (ENKTL). However, the optimal combined chemotherapy regimen is still unknown. Our previous study reported that LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) combined with radiotherapy was a potentially effective and safe treatment regimen for early-stage ENKTL. Read More

View Article and Full-Text PDF

Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk.

Ann Hematol 2022 May 18. Epub 2022 May 18.

Department of Cancer Biology, Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL, 60153, USA.

Our understanding of MM genomics has expanded rapidly in the past 5-10 years as a consequence of cytogenetic analyses obtained in routine clinical practice as well as the ability to perform whole-exome/genome sequencing and gene expression profiling on large patient data sets. This knowledge has offered new insights into disease biology and is increasingly defining high-risk genomic patterns. In this manuscript, we present a thorough review of our current knowledge of MM genomics. Read More

View Article and Full-Text PDF

Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis.

Ann Hematol 2022 May 16. Epub 2022 May 16.

Bone Marrow Transplantation Department, Hospital Israelita Albert Einstein, Guaramomis 480/64, São Paulo, SP, CEP 04076-010, Brazil.

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for several malignant hematologic diseases and alternative donors, including haploidentical, play a significant role in HCT. Despite the increasing use of haplo-HCT with PTCy, some questions remain open. The objective of the present study was to investigate risk factors for adverse outcomes after haplo-HCT with PTCy. Read More

View Article and Full-Text PDF

Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.

Ann Hematol 2022 May 16. Epub 2022 May 16.

Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, 610041, Chengdu, China.

High-dose chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) is generally the optimal option for patients with acute myeloid leukemia (AML). However, for favorable- and intermediate-risk patients, the regimen remains less understood due to graft versus host disease (GVHD) and increased non-relapsed mortality (NRM) caused by allo-HSCT. Additionally, the benefit of maintenance therapy has not yet been conclusively proven. Read More

View Article and Full-Text PDF

L-glutamine for sickle cell disease: more than reducing redox.

Ann Hematol 2022 May 14. Epub 2022 May 14.

Division of Hematology and Oncology, Department of Medicine, SUNY Upstate Medical University, 750 E Adams St, CWB Room 2284, Syracuse, NY, 13210, USA.

Oxidative stress is a major contributor to the pathophysiology of sickle cell disease (SCD) including hemolysis and vaso-occlusive crisis (VOC). L-glutamine is a conditionally essential amino acid with important roles, including the synthesis of antioxidants, such as reduced glutathione and the cofactors NAD(H) and NADP(H), as well as nitric oxide. Given the increased levels of oxidative stress and lower (NADH):(NAD +  + NADH) ratio in sickle erythrocytes that adversely affects the blood rheology compared to normal red blood cells, L-glutamine was investigated for its therapeutic potential to reduce VOC. Read More

View Article and Full-Text PDF

Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia.

Ann Hematol 2022 May 13. Epub 2022 May 13.

Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000, Lille, France.

View Article and Full-Text PDF

Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030.

Ann Hematol 2022 May 10. Epub 2022 May 10.

Mount Aubrun Hospital, Cambridge, MA, USA.

This study examines the burden of leukemia and its subtypes at the global, regional, and national levels in 21 world regions and 204 countries in the last three decades. The estimates of incidence, deaths, and age-standardized rates of leukemia for 21 regions and 204 countries for 1990-2019 were extracted from the Global Burden of Disease 2019 study. Average annual percentage change in 1990-2019 for 21 regions was utilized for projecting leukemia burden in 2030. Read More

View Article and Full-Text PDF

Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.

Ann Hematol 2022 May 9. Epub 2022 May 9.

Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 ShuaiFuYuan Street, Dongcheng District, Beijing, 100730, China.

Immune thrombocytopenia (ITP) patients are at risk developing to systemic lupus erythematosus (SLE) in the future. Our study attempted to explore the potential risk factors for the development from ITP to SLE in Chinese children by statistical analysis. This study was a retrospective case-control study. Read More

View Article and Full-Text PDF

Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.

Ann Hematol 2022 May 7. Epub 2022 May 7.

Department of Hematology, Gregorio Marañón General University Hospital, Madrid, Spain.

Despite advances in the understanding of the pathophysiology of cytomegalovirus (CMV) infection, it remains as one of the most common infectious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The aim of this study was to determine the genotype of cytokines and chemokines in donor and recipient and their association with CMV reactivation. Eighty-five patients receiving an allo-HSCT from an HLA-identical sibling donor were included in the study. Read More

View Article and Full-Text PDF

Neuroimaging of leptomeningeal myelomatosis: a rare and severe entity.

Ann Hematol 2022 May 7. Epub 2022 May 7.

Department of Neuroradiology, "Umberto I" Hospital, Nocera Inferiore, SK, Italy.

View Article and Full-Text PDF

A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.

Ann Hematol 2022 Apr 30. Epub 2022 Apr 30.

Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.

This phase 1b study evaluated glasdegib (100 mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for intensive chemotherapy. Of 72 patients enrolled, 12 were in a lead-in safety cohort (LIC) and 60 were in the AML and MDS (including CMML) expansion cohorts. In the LIC, the safety profile of glasdegib + azacitidine was determined to be consistent with those of glasdegib or azacitidine alone, with no evidence of drug-drug interaction. Read More

View Article and Full-Text PDF

Hepatitis B reactivation during ruxolitinib treatment.

Ann Hematol 2022 Apr 30. Epub 2022 Apr 30.

Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Rue du Bugnon 46, CH-1011, Lausanne, Switzerland.

View Article and Full-Text PDF

Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.

Ann Hematol 2022 Apr 29. Epub 2022 Apr 29.

Department of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100005, China.

View Article and Full-Text PDF

Characteristics of Sweet syndrome in patients with or without malignancy.

Ann Hematol 2022 Apr 28. Epub 2022 Apr 28.

Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, South Korea.

Sweet syndrome is a neutrophilic dermatosis occasionally associated with malignancies. Due to its rarity, the clinical features of Sweet syndrome are still unclear. Thus, we aimed to analyze clinical features, treatment, and outcomes of these patients according to associated disease. Read More

View Article and Full-Text PDF

Does size matter? Two new deletions in the HBB gene cause β-thalassemia.

Ann Hematol 2022 Apr 25. Epub 2022 Apr 25.

Hematology Service, Hospital Clínico San Carlos, C/Profesor Martín Lagos s/n, 28040, Madrid, Spain.

Most β-thalassemias are caused by mutations involving one or a limited number of nucleotides within the gene or its adjacent regions. They can be substitutions or deletions; in these cases, the loss ranges from a single nucleotide to even the entire HBB gene, so we wonder if the phenotype is due to the size of the deletion or the location of the mutation. To clarify this, we present two new deletions in the β-globin gene that cause β-thalassemia. Read More

View Article and Full-Text PDF

Bilateral deafness in NK/T-cell lymphoma: EBV DNA prevailed over magnetic resonance imaging.

Ann Hematol 2022 Apr 25. Epub 2022 Apr 25.

Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China.

View Article and Full-Text PDF

Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.

Ann Hematol 2022 Apr 23. Epub 2022 Apr 23.

Department of Hematology, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Guangzhou Road 300#, Nanjing, 210029, Jiangsu Province, China.

Adult pure red cell aplasia (PRCA) is a rare syndrome characterized by a severe normocytic anemia, reticulocytopenia, and absence of erythroblasts from bone marrow. The standard treatment has not yet been established for PRCA, although cyclosporine (CsA), corticosteroids (CS) showed a response in PRCA. We retrospectively analyzed the clinical data of 60 primary and 40 secondary adult patients with acquired PRCA. Read More

View Article and Full-Text PDF

Comparison of daily oral iron replacement therapy with every other day treatment in female reproductive age patients with iron-deficiency anemia.

Ann Hematol 2022 Apr 23. Epub 2022 Apr 23.

Department of Adult Hematology, Gazi University Faculty of Medicine, Beşevler, 06500, Ankara, Turkey.

Iron-deficiency anemia (IDA) is accepted as the most common cause of anemia in the world. The main goals of iron replacement therapy are to normalize the hemoglobin level and to replace iron stores. Current guidelines for treating iron deficiency recommend daily divided doses of iron to increase absorption. Read More

View Article and Full-Text PDF

Left atrial deformation indices in β-thalassemia major patients.

Ann Hematol 2022 Apr 23. Epub 2022 Apr 23.

First Department of Cardiology, General Hospital of Athens Ippokrateio, National and Kapodistrian University of Athens, 114 Vasilissis Sofias Avenue, 11527, Attica, Athens, Greece.

The presence of atrial cardiomyopathy in β-thalassemia major (β-TM) patients complicates their clinical condition. The diagnosis is challenging even with cardiac magnetic resonance (CMR) imaging. Novel echocardiographic techniques are applied to increase the diagnostic yield. Read More

View Article and Full-Text PDF

Screening for hereditary spherocytosis in daily practice: what is the best algorithm using erythrocyte and reticulocyte parameters?

Ann Hematol 2022 Apr 22. Epub 2022 Apr 22.

Department of Clinical Chemistry. LHUB-ULB, Université Libre de Bruxelles (ULB), 322, Rue Haute, 1000, Brussels, Belgium.

Hereditary spherocytosis (HS) is the most common inherited chronic haemolytic anaemia in Northern Europe. During the last decade, additional erythrocyte and reticulocyte parameters have been developed on last-generation haematology analysers, leading to many publications about their effectiveness as a HS screening tool. For the first time on an independent cohort, we evaluated and compared the effectiveness of six published algorithms for the screening of HS using the UniCel DxH800 (Beckman-Coulter) and the XN-9000 (Sysmex) and determined which algorithm could be the most suitable in our daily clinical practice. Read More

View Article and Full-Text PDF